Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers
Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
Participant gender:
Summary
As a result of our previous NCRN study (ABC-02) cisplatin and gemcitabine (CisGem) is likely
to become the international standard of care for patients with advanced biliary tract cancer
(submitted: ASCO 2009).
This study, ABC-03, will determine whether the addition of cediranib(an oral Vascular
Endothelial Growth Factor Receptor inhibitor) to CisGem will improve the time to disease
progression in this patient group.